Stocktoria
FRACTYL HEALTH, INC. GUTS
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2024-02-02
FRACTYL HEALTH, INC. financials (annual)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0 | $93,000 | $120,000 |
| Gross profit | — | $43,000 | $43,000 |
| R&D expense | $74.5M | $70.5M | $38.0M |
| SG&A expense | $22.3M | $23.1M | $12.8M |
| Operating income | -$96.8M | -$93.5M | -$50.8M |
| Income tax | $0 | $0 | $0 |
| Net income | -$141.0M | -$68.7M | -$77.1M |
| EPS (diluted) | $-1.86 | $-1.62 | $-45.29 |
| Operating cash flow | -$90.3M | -$65.5M | -$42.8M |
| Free cash flow | -$90.9M | -$67.3M | -$43.2M |
| Cash & equivalents | $81.5M | $67.5M | $33.2M |
| Inventory | — | $73,000 | $73,000 |
| Total assets | $121.4M | $108.1M | $76.2M |
| Total liabilities | $111.9M | $79.7M | $113.9M |
| Shareholders' equity | $9.5M | $28.4M | -$325.1M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue growth | -100.0% | -22.5% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.